Biomedical Sector Revenue & Growth in H1, 2021

• The charts below cover 195 listed and OTC companies, emerging stocks inclusive, in the biomedical related and bio-agricultural sectors in Taiwan.
• Total revenue up 18% to TWD$156.7 billion in H1, 2021, as opposed to TWD$132.8 billion of 185 companies, which posted in H1 last year.
• Total revenue Q2, 2021: TWD$80.1bn, a 14.9% increase compared to TWD$69.8bn same time last year.
• Top 3 by product sales in H1, 2021: Workout equipment & Health supplement 25.5%, Medical device R&D, Manufacturing 23.7%, Bio-pharmaceuticals 18.9%.

Source: MOPS, compiled by IBMI/RBMP

Top 20 by revenue H1, 2021: Listed companies

Top 20 by revenue H1, 2021: OTC companies

Top 20 by by revenue H1, 2021: Emerging stocks

*UBI Pharma and Medimaging Integrated Solution became Taipei Exchange Emerging Stock Board listed on 23 June and 16 April, 2021; revenue not available in Q1 and Q2.

Source: MOPS, compiled by IBMI/RBMP